Moreover, the elevated level of CCT2 and RPL17, observed as a result of μ-21 and μ-17 treatment, respectively, might represent a potential mechanism to counteract colon adenocarcinoma progression in later stages, since the decreased expression of these two proteins is associated with advanced colon adenocarcinoma staging, according to GEPIA3 data (Figure S10d,f). The gene discussed is CCT2; the disease is colon adenocarcinoma.